EVMNNYSEPharmaceutical PreparationsUS GAAP · USD

Evommune, Inc.

Evommune, Inc. is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory diseases. Its lead programs are aimed at chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis, with a pipeline built around differentiated product candidates and external licensing collaborations.

Kysy yhtiöstä
Liikevaihto13,0milj. USD
+85,7 %v/v
Liikevoitto (EBIT)−81,1milj. USD
−15,8 %v/v
EBIT-marginaali−623,6%
+376,6 %-yks.v/v
Nettotulos−68,9milj. USD
−3,1 %v/v
Vapaa kassavirta−76,7milj. USD
−31,6 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2024–2025

−100−80−60−40−20020milj. USD2024: 7,0 milj. USD2024: EBIT −70 milj. USD20242025: 13 milj. USD2025: EBIT −81 milj. USD202513−81
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Clinical-stage product candidates0 %

Lead therapeutic programs in human clinical development for chronic inflammatory diseases.

Licensed collaboration revenue100 %

Upfront and milestone payments from regional or global licensing agreements.

Preclinical pipeline0 %

Earlier-stage assets and discovery programs intended to broaden the portfolio.

Asiakkaat

Evommune does not yet commercialize approved products, so its current counterparties are mainly licensing partners rather than end-patients or hospitals. The company’s future customers would be physicians, specialty clinics, and healthcare systems treating chronic inflammatory diseases, while near-term value creation depends on pharma partners that fund development and commercialization rights.

Licensing and collaboration partners

Pharma partners that pay upfront fees, milestones, and royalties for regional or global rights to Evommune assets.

Future prescribers in dermatology and gastroenterology

Specialists who would prescribe approved therapies for CSU, AD, and UC based on efficacy and safety.

Patients with chronic inflammatory disease

End users of the therapies, especially patients needing better long-term control of inflammation.

Clinical development and research collaborators

CROs, CDMOs, and scientific partners that support trials, manufacturing, and discovery work.

Strategia

Evommune’s strategy is to advance a small number of differentiated inflammation programs through clinical proof-of-concept while broadening the pipeline with in-licensed assets. The company is also using regional partnerships to share development risk, preserve capital, and extend the commercial reach of its programs.

Advance Phase 2 clinical programsLyhyt aikaväli

Clinical validation is the main value inflection point for a pre-commercial biotech.

Expand through partnerships and licensingLyhyt aikaväli

External collaborations can fund development and reduce capital intensity.

Broaden the pipeline with preclinical assetsKeskipitkä aikaväli

A wider portfolio can improve long-term growth and reduce single-asset dependence.

Maantiede

Evommune is headquartered in the United States and operates as a U.S.-based clinical-stage biotech company. Its disclosed commercial geography is partnership-driven: Maruho holds rights to EVO756 in Greater China and certain other Asian countries, while AprilBio granted Evommune a worldwide license to EVO301. The company currently has no product sales geography because it has not commercialized any products.

Riskit

Evommune is a pre-revenue biotech with no approved products, so its success depends on clinical outcomes, regulatory approvals, and access to capital. The company also faces partner concentration, competitive pressure from better-funded drug developers, and execution risk in building future commercialization capabilities if any asset is approved.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Clinical development failure1Financing and liquidity pressure2Partner execution risk3Commercialization build-out risk4Competitive intensity5
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Clinical development failureVaikutus: KriittinenTodennäköisyys: Kohtalainen

    Lead assets are still in Phase 2, so efficacy or safety setbacks could eliminate value.

    Kohdistuu: EVO756 and EVO301

  2. Financing and liquidity pressureVaikutus: KorkeaTodennäköisyys: Korkea

    The company has incurred losses since inception and has no product revenue.

    Kohdistuu: Corporate funding runway

  3. Partner execution riskVaikutus: KorkeaTodennäköisyys: Matala

    Regional and global licensing partners control parts of development and commercialization.

    Kohdistuu: Maruho and AprilBio agreements

  4. Commercialization build-out riskVaikutus: KorkeaTodennäköisyys: Matala

    If approved, Evommune lacks sales, marketing, and distribution infrastructure.

    Kohdistuu: Future product launch

  5. Competitive intensityVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Large biotech and pharma companies can outspend Evommune in trials and market access.

    Kohdistuu: Chronic inflammation and immunology markets

Kirjanpito

Harkinnanvaraiset erät
License revenue recognition

Revenue is currently driven by collaboration and license arrangements, which can be timing-sensitive.

Vaikutus: Can create lumpy quarterly results

Accrued research and development expenses

Clinical and CRO/CDMO costs are estimated before invoices are finalized.

Vaikutus: Affects operating expense and net loss

Fair value of preferred stock forward and warrant liabilities

Derivative-style instruments are remeasured through earnings.

Vaikutus: Can add non-cash volatility to reported results

Stock-based compensation

Equity awards are a meaningful cost for a development-stage biotech.

Vaikutus: Raises G&A and R&D expense

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

ImageneBio, Inc.

IMA · Biological Products, (No Diagnostic Substances)

Inmune Bio, Inc.

INMB · Biological Products, (No Diagnostic Substances)

Equillium, Inc.

EQ · Pharmaceutical Preparations

Avalo Therapeutics, Inc.

AVTX · Pharmaceutical Preparations

Apogee Therapeutics, Inc.

Biological Products, (No Diagnostic Substances)

Q32 Bio Inc.

QTTB · Pharmaceutical Preparations

Päivitetty: 24.9.2026